SCHEMBL7053038

SCHEMBL7053038

O=[PH2]C(O)(CSc1ccc2ccccc2n1)C(Cc1ccccc1)C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRNP P04156 6/20 0.48
RXFP1 Q9HBX9 5/20 0.48
KDM4E B2RXH2 2/20 0.48
NPSR1 Q6W5P4 4/20 0.46
MAPK10 P53779 2/20 0.46
RAB9A P51151 2/20 0.45
ALDH1A1 P00352 6/20 0.43
KMT2A Q03164 5/20 0.40
MEN1 O00255 3/20 0.40
L3MBTL1 Q9Y468 2/20 0.37
HPGD P15428 2/20 0.37
SMN1; SMN2 Q16637 3/20 0.36
LMNA P02545 2/20 0.36
PTBP1 P26599 1/20 0.36
KCNK2 O95069 1/20 0.36
MAPT P10636 2/20 0.35
TDP1 Q9NUW8 2/20 0.35
THRB P10828 1/20 0.34
PTPN7 P35236 1/20 0.34
DUSP3 P51452 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7048093 0.89 RXFP1 (0.46) PRNPRXFP1KDM4ENPSR1MAPK10
SCHEMBL7050068 0.87 RXFP1 (0.44) PRNPRXFP1KDM4ENPSR1MAPK10
SCHEMBL7049811 0.86 PRNP (0.47) PRNPRXFP1KDM4ENPSR1MAPK10
SCHEMBL7048994 0.86 PRNP (0.51) PRNPRXFP1KDM4ENPSR1MAPK10
SCHEMBL7047077 0.81 RXFP1 (0.43) PRNPRXFP1KDM4ENPSR1MAPK10
SCHEMBL7051722 0.81 PPARG (0.43) RXFP1KDM4EALDH1A1LMNAMAPT
SCHEMBL7049090 0.77 PRNP (0.50) PRNPRXFP1KDM4ENPSR1MAPK10
SCHEMBL7434013 0.71 PRNP (0.48) PRNPRXFP1KDM4ENPSR1MAPK10
SCHEMBL7051083 0.69 PRNP (0.48) PRNPRXFP1KDM4ENPSR1MAPK10
SCHEMBL7046330 0.68 PRNP (0.47) PRNPRXFP1KDM4ENPSR1MAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030212067-A1 Matrix metalloprotease inhibitors CASTELHANO ARLINDO LUCAS (US) 2003-11-13 US disclosed
US-6579890-B1 Matrix metalloprotease inhibitors SYNTEX (U.S.A.) INC. 2003-06-17 US disclosed
US-6037472-A FOR TREATING DISEASE-STATES CHARACTERIZED BY EXCESSIVE ACTIVITY OF MATRIX METALLOPROTEASES SUCH AS RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTAL DISEASE, ABERRANT ANGIOGENESIS, TUMOR INVASION AND METASTASIS SYNTEX (U.S.A.) INC. (US) 2000-03-14 US disclosed
EP-0726903-B1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX INC (US) 1997-07-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212067-A1 Matrix metalloprotease inhibitors MMP7, MMP1, MMP3 PRNP 327/4885RXFP1 738/4885KDM4E 3133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.